Of note, a current clinical trial is ongoing to evaluate the combination of atezolizumab (humanized IgG1 antibody against PD-L1) and bevacizumab (monoclonal antibody developed against VEGF) in patients with recurrent or metastatic HNSCC (ATHENA, NCT03818061). Here, CD274 is linked to head and neck squamous cell carcinoma.